Navigation Links
K-V Pharmaceutical Company Announces Comprehensive Patient Assistance Program for Makena™
Date:3/8/2011

r materially from those set forth or implied by the forward-looking statements and related assumptions.

Such factors include (but are not limited to) the following:

  1. The Company's ability to successfully complete the proposed private placement of senior secured notes as described in our press release dated March 1, 2011;
  2. the ability to continue as a going concern;
  3. the terms of our secured loan agreement with U.S. Healthcare I, L.L.C. and U.S. Healthcare II, L.L.C. (together, the "Lenders"), as more fully described in Item 1— "Business—(b) Significant Recent Developments—Financing" in the Company's Annual Report on Form 10-K for the year ended March 31, 2010 (the "Form 10-K"), as amended, could have an adverse effect on us if we are not able to refinance it or repay it at maturity on March 20, 2013, or earlier if we experience an event of default that is not waived by the Lenders or if a waiver expires and is not extended, and such terms contain numerous affirmative and negative covenants and conditions that must be met in order to avoid default and/or to qualify for additional loan tranches, and there are substantial risks of triggering defaults with respect to such covenants and/or the occurrence or non-occurrence of conditions that would preclude the Company from being able to draw down additional loan tranches, which could materially adversely impact the Company, lead to foreclosure on the Company assets acting as collateral for the loan agreement, and adversely affect the Company's ability to operate, including  the launch of Makena™;
  4. the possibility of not obtaining FDA approvals or delay in obtaining FDA approvals;
  5. new product development and launch, including the possibility that any product launch may be delayed or unsuccessful, including with respect to Makena™;
  6. acceptance of and demand for the Company's new pharmaceutical products, includ
    '/>"/>

SOURCE K-V Pharmaceutical Company
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Friday, March 11
2. Merz Pharmaceuticals Introduces Comprehensive Programs to Provide Patients With Financial Assistance for Xeomin® (incobotulinumtoxinA)
3. Vanda Pharmaceuticals Receives Orphan Drug Designation in Europe for tasimelteon
4. Pacira Pharmaceuticals to Present at the Barclays Capital 2011 Global Healthcare Conference
5. Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2010 Results
6. AcelRx Pharmaceuticals to Present at the Cowen and Company 31st Annual Health Care Conference
7. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Fourth Quarter and Year End 2010 Financial Results on Wednesday, March 9, 2011 at 8:30 a.m. ET
8. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
9. Jazz Pharmaceuticals Announces Fourth Quarter and Full Year 2010 Results
10. Reportlinker Adds The 2011 Top Ten Worlds Leading Pharmaceutical Companies
11. Isis Pharmaceuticals to Present at the Roth 23rd Annual OC Growth Stock Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com ... is available in its catalogue: ... Advanced Drug Delivery Systems -- Focus on ... STUDY OBJECTIVES A ...
(Date:1/15/2014)... 15, 2014  Zafgen, Inc., a leading biopharmaceutical company ... obese patients, today announced initial results from its ... of methionine aminopeptidase 2 (MetAP2), in patients with ... obesity.  These results showed improvements in body weight, ...
(Date:1/14/2014)... HeartWare International, Inc . (NASDAQ: ... circulatory support technologies that are revolutionizing the treatment of ... for the fourth quarter of 2013 will be approximately ... $208 million. "Our full-year revenue growth of ...
Breaking Medicine Technology:Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4
... 1, 2007 - Introgen Therapeutics, Inc.,(NASDAQ:INGN) reported promising ... novel investigational mda-7/IL-24 tumor,suppressor agent, in patients with ... were presented today at the,annual meeting of the ... 22-patient trial, INGN 241 induced killing in all ...
... Inc.,(TSX: TLN) announced today that preliminary data from ... cancer,patients was published in abstract form as part ... Meeting in Chicago,Illinois. In the Phase I dose ... two ovarian, one duodenal and one,glioma), that had ...
Cached Medicine Technology:Introgen Reports Promising Phase 1/2 Clinical Results With INGN 241,in Patients With Advanced Solid Tumors 2Introgen Reports Promising Phase 1/2 Clinical Results With INGN 241,in Patients With Advanced Solid Tumors 3Thallion Announces Publication of ECO-4601 Phase I/II Clinical Data,at ASCO 2Thallion Announces Publication of ECO-4601 Phase I/II Clinical Data,at ASCO 3
(Date:4/17/2014)... Experimental Biology and Medicine a multidisciplinary ... Paul Kenis in the Institute of Genomic Biology ... Illinois Urbana-Champaign describe their recent work on subcellular ... of cell functions including energy metabolism, signaling, and ... regulating normal cellular behavior, redox status has been ...
(Date:4/17/2014)... Colo. (April 17, 2014) Two recent papers ... researcher and colleagues may help scientists develop treatments ... Yellow fever, Japanese encephalitis and other disease-causing flaviviruses. ... biochemistry and molecular genetics at the School of ... Howard Hughes Medical Institute, and colleagues recently published ...
(Date:4/17/2014)... Pediatrician-in-Chief Jon McCullers, MD, was recently invited to ... Nature Reviews Microbiology , one of the ... world-renowned infectious disease specialist, and chair of the ... Health Science Center, analyzed the epidemiology and microbiology ... pandemics, as well as more recent 2009 novel ...
(Date:4/17/2014)... NY, April 17, 2014U.S. military personnel who served ... impact" concussive traumatic brain injury (TBI) were compared ... for other medical reasons. Differences in measures of ... 6-12 months after injury are reported in an ... peer-reviewed journal from Mary Ann Liebert, Inc., publishers. ...
(Date:4/17/2014)... million older Americans suffer from depression, often brought on ... research a project that followed the lives of ... found that Internet use among the elderly can reduce ... , "That,s a very strong effect," said Shelia Cotten, ... and media who led the project. "And it all ...
Breaking Medicine News(10 mins):Health News:Live cell imaging reveals distinct alterations of subcellular glutathione potentials 2Health News:CU researchers discover target for treating dengue fever 2Health News:Long-term effects of battle-related 'blast plus impact' concussive TBI in US military 2Health News:Internet use can help ward off depression among elderly 2
... A short-term, very-high dose regimen of the immune-suppressing drug ... in most of a small group of patients studied ... disease, Johns Hopkins researchers report. The findings in nine ... suggest new ways to treat a disease that tends ...
... Bulge with Hoodia and Bitter Orange, LOS ... fatty,and unhealthy coffee creamers, Java Solutions today announces ... creamer to start your day off,with a weight-loss ... of,French vanilla and non-fat buttercream with Hoodia, a ...
... to Solantic Board, JACKSONVILLE, Fla., June 10 ... urgent care, today announced,the appointment of Tom Scully ... a General Partner with New York City Private ... largest private equity investor in,healthcare. In addition, Mr. ...
... 10 Christine Carson Filipovich, a,graduate of Venture ... Nursing Resources, Inc., was honored last month with ... Bolton School of Nursing at,Case Western Reserve University ... an alumna or alumnus "who has demonstrated,outstanding leadership ...
... no longer just for doctors as PointOne ... WAUWATOSA, Wis., June 10 PointOne Systems, ... tool, known as,RedBox Technology, will begin providing reports ... dramatic change from the industry,s focus,on hospitals, research ...
... Information technology has the power,"to transform data ... Co. executive Carly Fiorina once explained., ... Ingenious Med,s IM Quality,Measures(TM), a software package ... capture, report, and submit quality performance,metrics. Physicians ...
Cached Medicine News:Health News:'HiCy' drug regimen reverses ms symptoms in selected patients 2Health News:'HiCy' drug regimen reverses ms symptoms in selected patients 3Health News:Leaner Coffee Creamer Boosts Metabolism and Curbs Appetite 2Health News:Healthcare Veteran Joins Solantic Board of Directors 2Health News:Nursing Entrepreneur Whose Business Career Was Spurred by Venture Training is Honored with Alumna Award from Case Western Reserve University 2Health News:PointOne Launches New Business Direction, Healthcare Analytics Beyond Hospitals 2Health News:Ingenious Med's IM Quality Measures(TM) Delivers Insight About Hospitalist Performance 2Health News:Ingenious Med's IM Quality Measures(TM) Delivers Insight About Hospitalist Performance 3Health News:Ingenious Med's IM Quality Measures(TM) Delivers Insight About Hospitalist Performance 4
Supplemental instrument to the Small Joint Arthroplasty System....
... System utilizes the same proven materials found ... The SR™ Hand Implant System provides advantages ... minimal bone resection, surface replacement of the ... and/or repositioning of the ligamentous soft tissues, ...
Anatomic implant shape and easy-to use instrumentation promote implant alignment, stability, and restored joint kinematics....
The NeurOptics Pupillometer is a portable instrument used to measure pupils to screen candidates for refractive procedures and other ophthalmic applications....
Medicine Products: